To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
Active, not recruiting · NCT07098897 · Registry updated 2025-08-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-08-01 | NCT07098897 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The Affiliated Hospital of Xuzhou Medical University | 68 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated hospital of Xuzhou Medical University | Xuzhou | China | 1 |